Cytokinetics Inc
NASDAQ:CYTK

Watchlist Manager
Cytokinetics Inc Logo
Cytokinetics Inc
NASDAQ:CYTK
Watchlist
Price: 52.02 USD 3.52% Market Closed
Market Cap: 6.1B USD
Have any thoughts about
Cytokinetics Inc?
Write Note

Cytokinetics Inc
Other Non-Cash Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cytokinetics Inc
Other Non-Cash Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Non-Cash Items CAGR 3Y CAGR 5Y CAGR 10Y
Cytokinetics Inc
NASDAQ:CYTK
Other Non-Cash Items
$102.9m
CAGR 3-Years
26%
CAGR 5-Years
26%
CAGR 10-Years
42%
Abbvie Inc
NYSE:ABBV
Other Non-Cash Items
$7B
CAGR 3-Years
-10%
CAGR 5-Years
-6%
CAGR 10-Years
19%
Gilead Sciences Inc
NASDAQ:GILD
Other Non-Cash Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Other Non-Cash Items
-$419m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Non-Cash Items
$742.4m
CAGR 3-Years
37%
CAGR 5-Years
13%
CAGR 10-Years
4%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Non-Cash Items
$480.1m
CAGR 3-Years
24%
CAGR 5-Years
-6%
CAGR 10-Years
4%
No Stocks Found

Cytokinetics Inc
Glance View

Market Cap
6.1B USD
Industry
Biotechnology

Cytokinetics Inc., a clinical-stage biopharmaceutical company, is at the forefront of developing impactful treatments for muscle diseases, leveraging its pioneering expertise in muscle biology and discovery. Founded in 1999 and headquartered in South San Francisco, California, Cytokinetics focuses on harnessing the power of muscle function through its innovative therapies. The company’s lead product candidates, including omecamtiv mecarbil and reldesemtiv, are specifically designed to improve muscle performance in patients suffering from serious conditions like heart failure and amyotrophic lateral sclerosis (ALS). As the demand for effective treatments grows, Cytokinetics is leading the charge to enhance muscle function, aiming not just to prolong life, but to improve patients' quality of life. For investors, Cytokinetics presents a unique opportunity within the growing biopharmaceutical market. The company has strategically partnered with industry leaders, including Amgen, to accelerate the development of its therapeutic portfolio, significantly bolstering its credibility and pipeline potential. With increasing recognition of the importance of muscle health, Cytokinetics stands at an advantageous juncture, positioned to leverage its scientific know-how to unlock substantial value. As clinical trials progress and the company moves closer to potential commercialization, investors have the potential to benefit from Cytokinetics’ innovative approach to addressing unmet medical needs, making it a compelling consideration for those looking to invest in the future of healthcare innovation.

CYTK Intrinsic Value
27.1 USD
Overvaluation 48%
Intrinsic Value
Price

See Also

What is Cytokinetics Inc's Other Non-Cash Items?
Other Non-Cash Items
102.9m USD

Based on the financial report for Sep 30, 2024, Cytokinetics Inc's Other Non-Cash Items amounts to 102.9m USD.

What is Cytokinetics Inc's Other Non-Cash Items growth rate?
Other Non-Cash Items CAGR 10Y
42%

Over the last year, the Other Non-Cash Items growth was -3%. The average annual Other Non-Cash Items growth rates for Cytokinetics Inc have been 26% over the past three years , 26% over the past five years , and 42% over the past ten years .

Back to Top